Congo vs Europe (WHO region): Previously treated cases tested for RR-/MDR-TB
Congo
100.0%
in 2024
Europe (WHO region)
90.0%
in 2024
Congo rank
1st
Europe (WHO region) rank
2nd
Previously treated cases tested for RR-/MDR-TB over time
- Congo
- Europe (WHO region)
How they compare
Congo currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Congo's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 3 times across 11 shared years of data; in 2013 it was Europe (WHO region) ahead.
Congo ranks 1st and Europe (WHO region) ranks 2nd of 180 countries.
Across the 2 decades both report, Congo averaged higher in 1 and Europe (WHO region) in 1.
Head to head by decade
| Decade | Congo | Europe (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 77.2% | 60.7% | 16.5% | Congo |
| 2020s | 69.8% | 93.8% | 24.0% | Europe (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Congo or Europe (WHO region)?
- Congo, at 100.0% against 90.0% in Europe (WHO region) as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Congo and Europe (WHO region)?
- 10.0%, with Congo ahead.
- How many years of comparable data are there for Congo and Europe (WHO region)?
- 11 years are reported by both, from 2013 to 2024.
- How do Congo and Europe (WHO region) rank globally for previously treated cases tested for rr-/mdr-tb?
- Congo ranks 1st and Europe (WHO region) ranks 2nd of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.